Boehringer lays off or relocates sales staff for its Humira biosimilar Cyltezo (adalimumab biosimilar).
In a sign of how difficult it is to get adoption of less-expensive versions of the blockbuster drug Humira, Boehringer Ingelheim is laying off or relocating its sales staff for its drug Cyltezo, the company confirmed.
The company did not say how many employees are being laid off. One source said about 70 employees are affected. After two decades on the U.S. market, Humira last year began facing competition from multiple less-expensive biosimilar versions of the blockbuster therapy. For complicated policy reasons, pharmacy benefit managers make more money from Humira than they do biosimilars, so PBMs favor the branded Humira by giving them better formulary placement compared to biosimilars.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins